Nykode Therapeutics ASA (NYKD) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.057x

Based on the latest financial reports, Nykode Therapeutics ASA (NYKD) has a cash flow conversion efficiency ratio of -0.057x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-59.64 Million ≈ $-6.28 Million USD) by net assets (Nkr1.05 Billion ≈ $110.32 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Nykode Therapeutics ASA (NYKD) liquidity interval to measure how many days the company can operate on defensive assets alone.

Nykode Therapeutics ASA - Cash Flow Conversion Efficiency Trend (2016–2024)

This chart illustrates how Nykode Therapeutics ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Nykode Therapeutics ASA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Nykode Therapeutics ASA ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Viva Leisure Ltd AU:VVA	0.366x
Schloss Wachenheim AG F:SWA	-0.008x
Mobile Infrastructure Corporation NYSE MKT:BEEP	0.007x
Macpower CNC Machines Limited NSE:MACPOWER	0.005x
Union Bankshares Inc NASDAQ:UNB	0.125x
Noroo Paint KO:090350	-0.029x
Kino Polska TV SA WAR:KPL	0.086x
Thuan Duc JSC VN:TDP	0.282x

Annual Cash Flow Conversion Efficiency for Nykode Therapeutics ASA (2016–2024)

The table below shows the annual cash flow conversion efficiency of Nykode Therapeutics ASA from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Nykode Therapeutics ASA market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Nkr136.21 Million ≈ $14.33 Million	Nkr-51.22 Million ≈ $-5.39 Million	-0.376x	+33.35%
2023-12-31	Nkr171.26 Million ≈ $18.02 Million	Nkr-96.62 Million ≈ $-10.17 Million	-0.564x	-328.11%
2022-12-31	Nkr157.02 Million ≈ $16.52 Million	Nkr-20.69 Million ≈ $-2.18 Million	-0.132x	-2314.20%
2021-12-31	Nkr194.06 Million ≈ $20.42 Million	Nkr1.16 Million ≈ $121.54K	0.006x	-99.41%
2020-12-31	Nkr178.85 Million ≈ $18.82 Million	Nkr180.27 Million ≈ $18.97 Million	1.008x	+365.51%
2019-12-31	Nkr242.56 Million ≈ $25.52 Million	Nkr-92.08 Million ≈ $-9.69 Million	-0.380x	+15.31%
2018-12-31	Nkr140.07 Million ≈ $14.74 Million	Nkr-62.78 Million ≈ $-6.61 Million	-0.448x	-45.30%
2017-12-31	Nkr203.53 Million ≈ $21.42 Million	Nkr-62.78 Million ≈ $-6.61 Million	-0.308x	-347.33%
2016-12-31	Nkr23.19 Million ≈ $2.44 Million	Nkr-1.60 Million ≈ $-168.25K	-0.069x	--

About Nykode Therapeutics ASA

OL:NYKD Norway Biotechnology

Market Cap

$108.07 Million

Nkr1.03 Billion NOK

Market Cap Rank

#18987 Global

#166 in Norway

Share Price

Nkr3.15

Change (1 day)

+0.32%

52-Week Range

Nkr1.47 - Nkr3.88

All Time High

Nkr91.25